Development and validation of a utility weighting function for the patient-oriented prostate utility scale (PORPUS)

Medical Decision Making

Volumn 32, Issue 1, 2012, Pages 11-30

  Tomlinson, George ^a,b,c,e   Bremner, Karen E ^c,e   Ritvo, Paul ^b   Naglie, Gary ^a,d   Krahn, Murray D ^a,b,c,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

preference weights; prostate cancer; utility measurement; valuation functions

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD; DECISION MAKING; HEALTH STATUS; HUMAN; INTERVIEW; MALE; MIDDLE AGED; PROSTATE TUMOR; QUESTIONNAIRE; STANDARD; STATISTICAL MODEL; VALIDATION STUDY;

AGED; DECISION MAKING; HEALTH STATUS; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES;

EID: 84856619370     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X11407203     Document Type: Conference Paper

References (54)

1. Schroder FH, Wildhagen MF. Screening for prostate cancer: evidence and perspectives. BJU Int. 2001 ; 88: 811-7 (Pubitemid 33071051)
2. Parkinson MC, Bott SRJ, Montironi R, Melia J. Screening for prostatic cancer and its evolution within Britain. J Pathol. 2002 ; 197: 139-42 (Pubitemid 34567599)
3. Donovan JL, Frankel SJ, Neal DE, Hamdy FC. Screening for prostate cancer in the UK seems to be creeping in by the back door [editorial]. BMJ. 2001 ; 323: 763-4
4. Krahn MD, Bremner KE, Asaria J, et al. The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology. 2002 ; 60: 258-63 (Pubitemid 34831769)
5. Fleshner N, Rakovitch E, Klotz L. Differences between urologists in the United States and Canada in the approach to prostate cancer. J Urol. 2000 ; 163: 1461-6 (Pubitemid 30226296)
6. Donovan JL, Frankel SJ, Faulkner A, Selley S, Gillatt D, Hamdy FC. Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom. BMJ. 1999 ; 318: 299-300 (Pubitemid 29195138)
7. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 ; 360: 1310-9
8. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 ; 360: 1320-8
9. Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P. Making decisions about treatment for localized prostate cancer. BJU Int. 2002 ; 89: 255-60 (Pubitemid 34158457)
10. Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what's important. J Gen Int Med. 2000 ; 15 (10). 694-701
11. Sanda M, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med. 2008 ; 358: 1250-61 (Pubitemid 351439226)
12. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg J. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 1993 ; 269: 2650-9
13. Cantor SB, Spann SJ, Volk RJ, Cardenas MP, Warren MM. Prostate cancer screening: a decision analysis. J Fam Pract. 1995 ; 41: 33-41
14. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: a decision analytic view. JAMA. 1994 ; 272: 773-80 (Pubitemid 24275689)
15. Mold JW, Holtgrave DR, Bisonni RS, Marley DS, Wright RA, Spann SJ. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis. J Fam Pract. 1992 ; 34: 561-8 (Pubitemid 23046860)
16. Volk RJ, Cantor SB, Spann SJ, Cardenas MP, Warren MM. Preferences of husbands and wives for prostate cancer screening. Arch Fam Med. 1997 ; 6: 72-6 (Pubitemid 127440371)
17. Froberg DG, Kane RL. Methodology for measuring health-state preferences-II: scaling methods. J Clin Epidemiol. 1989 ; 42: 459-71 (Pubitemid 19165912)
18. Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis. 1987 ; 40: 593-600 (Pubitemid 17084806)
19. Revicki DA, Kaplan RM. Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Qual Life Res. 1993 ; 2: 477-87 (Pubitemid 24035220)
20. Feeny D. A utility approach to the assessment of health-related quality of life. Med Care. 2000 ; 38 (9). II-151-4
21. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems: Health Utilities Index. Pharmacoeconomics. 1995 ; 7: 490-502
22. Feeny DH, Torrance GW, Furlong WJ Quality of Life and Pharmacoeconomics in Clinical Trials. 2 nd ed.Philadelphia: Lippincott-Raven; 1996. p 239-52. Spilker B, ed. Philadelphia: Lippincott-Raven ; 1996: 239-52.
23. Kaplan RM, Anderson JP, Wu AW, Mathews C, Kozin F, Orenstein D. The Quality of Well-Being Scale: applications in AIDS, cystic fibrosis, and arthritis. Med Care. 1989 ; 27: S27 - S43
24. A new facility for the measurement of health related quality of life. Health Policy. 1990 ; 16: 199-208
25. Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions: Health Utilities Index. Pharmacoeconomics. 1995 ; 7: 503-20
26. Essink-Bot ML, Stouthard ME, Bonsel GJ. Generalizability of valuations on health states collected with the EuroQol questionnaire. Health Econ. 1993 ; 2: 237-46
27. Ferrer M, Suarez JF, Gueda F, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008 ; 72: 421-32
28. Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G. Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qual Life Res. 2007 ; 16: 509-22 (Pubitemid 46363692)
29. McTaggart-Cowan HM, Marra CA, Yang Y, et al. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Qual Life Res. 2008 ; 17: 453-62
30. Gold MR, Patrick DL, Torrance GW, et al In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost Effectiveness in Health and Medicine. New York ; 1996: 82-134.
31. Krahn M, Ritvo P, Irvine J, et al. Construction of the Patient-Oriented Prostate Utility Scale (PORPUS): a multiattribute health state classification system for prostate cancer. J Clin Epidemiol. 2000 ; 53: 920-30
32. Ritvo P, Irvine J, Naglie G, et al. Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer. J Clin Epidemiol. 2005 ; 58: 466-74 (Pubitemid 40544568)
33. Bennett KJ, Torrance GW, Tugwell P. Methodologic challenges in the development of utility measures of health related quality of life in rheumatoid arthritis. Control Clin Trials. 1991 ; 12: 118s - 28s
34. Mohide EA, Torrance GW, Streiner DL, Pringle DM, Gilbert R. Measuring the well being of family caregivers using the time trade-off technique. J Clin Epidemiol. 1988 ; 41: 475-82
35. Torrance G, Keresteci MA, Casey RW, Rosner AJ, Ryan N, Breton MC. Development and initial validation of a new preference-based disease-specific health-related quality of life instrument for erectile function. Qual Life Res. 2004 ; 13: 349-59 (Pubitemid 38392263)
36. Krahn MD, Ritvo P, Naglie IG, Irvine J, Trachtenberg J. Patient and expert quality of life ratings in the construction of an empirically-derived, domain-linked utility instrument for prostate cancer [abstract]. Med Decis Making. 1996 ; 16: 470
37. Bremner KE, Tomlinson G, Krahn MD. Marker states and a health state prompt provide modest improvements in the reliability and validity of the standard gamble and rating scale in prostate cancer patients. Qual Life Res. 2007 ; 16: 1665-75 (Pubitemid 350059903)
38. Froberg DG, Kane RL. Methodology for measuring health-state preferences-I: measurement strategies. J Clin Epidemiol. 1989 ; 42: 345-54 (Pubitemid 19133720)
39. Stevens K, McCabe C, Brazier J, Roberts J. Multi-attribute utility function or statistical inference models: a comparison of health state valuation models using the HUI2 classification system. J Health Econ. 2007 ; 26: 992-1002 (Pubitemid 47239111)
40. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002 ; 21: 271-92 (Pubitemid 34143147)
41. Dolan P. Modeling valuations for EuroQol Health States. Med Care. 1997 ; 35: 1095-108 (Pubitemid 127453463)
42. Busschbach JV, McDonnell J, Essink-Bot M-L, van Hout BA. Estimating parametric relationships between health state description and health valuation with an application to the EuroQol EQ-5D. J Health Econ. 1999 ; 18: 551-71
43. Torrance G, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multi-attribute preference functions for a comprehensive health state classification system: Health Utilities Index Mark 2. Med Care. 1996 ; 34: 702-22 (Pubitemid 126433265)
44. Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest. 1998 ; 114: 998-1007 (Pubitemid 28495893)
45. Revicki DA, Leidy NK, Brennan-Diemer F, Thompson C, Togias A. Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index. Qual Life Res. 1998 ; 7: 693-702 (Pubitemid 29089249)
46. Le Gales C, Buron C, Costet N, Rosman S. Development of a preference-weighted health status classification system in France: the Health Utilities Index 3. Health Care Manage Sci. 2002 ; 5: 41-51 (Pubitemid 41450999)
47. Furlong W, Feeny D, Torrance GW, Barr R, Horsman J Guide to Design and Development of Health-State Utility Instrumentation. Hamilton, Ontario, Canada: McMaster University ; 1990 :
48. McCabe CJ, Stevens KJ, Brazier JE. Utility scores for the Health Utilities Index Mark 2: an empirical assessment of alternative mapping functions. Med Care. 2005 ; 43: 627-35 (Pubitemid 40847300)
49. Novick MR, Lindley DV. Fixed-state assessment of utility functions. J Am Stat Assoc. 1979 ; 74 (366). 306-11
50. Alibhai SM, Krahn MD, Cohen MM, Fleshner NE, Tomlinson GA, Naglie G. Is there age bias in the treatment of localized prostate carcinoma?. Cancer. 2004 ; 100: 72-81 (Pubitemid 37553541)
51. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998 ; 36: 1002-12 (Pubitemid 128456439)
52. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000 ; 56: 899-905
53. Menzel P, Dolan P, Richardson J, Olsen JA. The role of adaptation to disability and disease in health state valuation: a preliminary normative analysis. Soc Sci Med. 2002 ; 55: 2149-58 (Pubitemid 36158948)
54. Dolan P, Sutton M. Mapping visual analogue scale health state valuations onto standard gamble and time trade-off values. Soc Sci Med. 1997 ; 44: 1519-30 (Pubitemid 27196507)